Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company was founded in 1969 and is based in Washington, the District of Columbia.
DHR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Danaher Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Danaher Corp ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Danaher Corp ended up being:
The company's debt burden, as measured by earnings divided by interest payments, is 19.17 -- which is good for besting 84.95% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
DHR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 33.8% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
BIO, NRC, ZYXI, ABT, and AZN can be thought of as valuation peers to DHR, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
UPDATE AVAILABLE ON-DEMAND According to the report by Allied Market Research, the Austria Flow Cytometry market is estimated to register a CAGR of 12.3% from 2015 to 2020. The research helps leading players and startups to devise new strategies based on
Danaher's (DHR) share price has seen a considerable increase recently, doubling within the past two years. Particularly interesting is the performance during the corona pandemic. Following a brief pullback in March, the stock of Danaher has risen well above its level before the corona crash. The price of the stock...
Maximilian Dorn on Seeking Alpha | October 1, 2020
A report by The Insight Partner's on the Immunohistochemistry Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the market
Thesis Repligen (NASDAQ: RGEN) trades at a rather high valuation, but there are still very good reasons to buy the company today. Repligen supports the biologics industry, which has started a period of strong secular growth that should fuel growing cash flows and earnings over the next several years. This...
Star Investments on Seeking Alpha | September 30, 2020
Overview of Global Research Antibodies Market: The Research Antibodies Market has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Research Antibodies Market size to maintain the average annual growth rate of 6.15% from